Integra LifeSciences (NASDAQ:IART) Stock Price Up 6.4% – Should You Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares rose 6.4% during mid-day trading on Friday . The company traded as high as $19.67 and last traded at $19.7420. Approximately 134,645 shares were traded during trading, a decline of 85% from the average session volume of 887,979 shares. The stock had previously closed at $18.56.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Truist Financial increased their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a report on Thursday, June 18th. Citigroup reiterated a “neutral” rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen cut Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $18.33.

Integra LifeSciences Stock Performance

The company has a market cap of $1.54 billion, a PE ratio of -3.06, a P/E/G ratio of 1.30 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The stock’s 50-day simple moving average is $17.28 and its 200 day simple moving average is $13.26.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business’s revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

Hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. boosted its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares in the last quarter. State of Tennessee Department of Treasury lifted its holdings in Integra LifeSciences by 7.9% in the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after acquiring an additional 1,964 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares in the last quarter. Capital Fund Management S.A. grew its stake in shares of Integra LifeSciences by 5.7% during the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after purchasing an additional 1,997 shares during the period. Finally, Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences during the 4th quarter worth $25,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.